ストックスクリーナーアプリを入手
94.23
1.96%
-1.7999
前日終値:
$96.03
開ける：
$96.23
24時間の取引高:
424.66K
Relative Volume:
0.61
時価総額：
$4.88B
収益：
$379.25M
当期純損益:
$-77.34M
株価収益率:
-58.45
EPS:
-1.6122
ネットキャッシュフロー:
$-27.87M
1週間 パフォーマンス:
+3.40%
1か月 パフォーマンス:
+17.61%
6か月 パフォーマンス:
+77.47%
1年 パフォーマンス:
+93.53%
1日の値動き範囲:
$93.19
$96.84
1週間の範囲:
$89.47
$96.84
52週間の値動き範囲:
$36.88
$96.84
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
名前
Mirum Pharmaceuticals Inc
セクター
電話
650-667-4085
住所
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
94.33 | 4.96B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.42 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.75 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.50 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.88 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.98 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-24 | 開始されました | TD Cowen | Buy |
| 2025-08-11 | 再開されました | Stifel | Buy |
| 2025-05-19 | 再開されました | H.C. Wainwright | Buy |
| 2024-04-17 | 開始されました | Stifel | Buy |
| 2023-12-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-11-13 | 開始されました | Morgan Stanley | Overweight |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 再開されました | Evercore ISI | Outperform |
| 2023-09-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-09-01 | 開始されました | Citigroup | Buy |
| 2021-09-20 | 開始されました | JP Morgan | Overweight |
| 2020-08-07 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-06-25 | 開始されました | Robert W. Baird | Outperform |
| 2019-08-12 | 開始されました | Citigroup | Buy |
| 2019-08-12 | 開始されました | Evercore ISI | Outperform |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | ROTH Capital | Buy |
| 2019-08-12 | 開始されました | Raymond James | Outperform |
すべてを表示
Mirum Pharmaceuticals Inc (MIRM) 最新ニュース
Mirum Pharmaceuticals stock hits all-time high at 95.75 USD By Investing.com - Investing.com Nigeria
Baird Updates Mirum Pharmaceuticals (MIRM) Valuation Following Beat-and-Raise Earnings Results - Insider Monkey
Mirum Pharmaceuticals stock hits all-time high at 95.75 USD - Investing.com
Mirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Emerald Advisers LLC - MarketBeat
14 Best Mid-Cap Growth Stocks to Buy Right Now - Insider Monkey
Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 52-Week HighHere's Why - MarketBeat
Mirum Pharmaceuticals (NASDAQ:MIRM) Insider Joanne Quan Sells 6,911 Shares - MarketBeat
CorMedix vs. Mirum Pharma: Which Rare-Disease Stock is the Better Buy? - sharewise.com
Mirum stock rises 7% in a week: Here's what you should know - MSN
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
23,566 Shares in Mirum Pharmaceuticals, Inc. $MIRM Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Dividend Watch: Will Mirum Pharmaceuticals Inc benefit from AI trendsJuly 2025 Fed Impact & Long-Term Safe Investment Plans - baoquankhu1.vn
Treasury Yields: Is Rush Enterprises Inc stock overvalued or fairly priced2025 Market Overview & Daily Volume Surge Signals - baoquankhu1.vn
Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Mirum Stock Rises 7% in a Week: Here's What You Should Know - Yahoo Finance
Mirum Pharmaceuticals stock hits all-time high at 91.99 USD By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals stock soars to all-time high of $48.94 - MSN
Mirum Pharmaceuticals stock hits all-time high at 91.99 USD - Investing.com
HC Wainwright Has Bullish Estimate for MIRM FY2025 Earnings - MarketBeat
Citizens reiterates Market Outperform rating on Mirum Pharmaceuticals stock By Investing.com - Investing.com UK
Income Plays: How correlated is MSPRK to the S P500July 2025 Volume & Expert Curated Trade Setup Alerts - baoquankhu1.vn
MIRM: Four pivotal clinical readouts and robust revenue growth position the pipeline for major expansion - TradingView — Track All Markets
Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026 - AOL.com
Assessing Mirum Pharmaceuticals (MIRM) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
A New Era in Rare Hepatology: The Deep-Dive Analysis of Mirum Pharmaceuticals (MIRM) - FinancialContent
Aug Highlights: Is Mirum Pharmaceuticals Inc 08D stock undervalued after correctionQuarterly Market Summary & Weekly High Return Stock Forecasts - Bộ Nội Vụ
3 Top Growth Stocks to Buy in the First Half of 2026 - Finviz
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent
Baird raises Mirum Pharmaceuticals stock price target to $95 on strong sales - Investing.com Canada
Mirum Pharmaceuticals reports $520 million in 2025 net product sales By Investing.com - Investing.com Nigeria
Baird Adjusts Mirum Pharmaceuticals Price Target to $95 From $88, Maintains Outperform Rating - marketscreener.com
Mirum Pharmaceuticals reports $520 million in 2025 net product sales - Investing.com
Mirum Pharmaceuticals stock exceeds FY25 guidance, TD Cowen reiterates Buy By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals stock exceeds FY25 guidance, TD Cowen reiterates Buy - Investing.com Nigeria
Mirum Pharmaceuticals announces preliminary unaudited 2025 results, demonstrating strong commercial growth and pipeline momentum - marketscreener.com
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth And Pipeline Momentum - TradingView — Track All Markets
Mirum Pharmaceuticals Announces Preliminary Unaudited 2025 Results, Demonstrating Strong Commercial Growth and Pipeline Momentum - FinancialContent
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - marketscreener.com
Will strong Livmarli uptake continue to aid MIRM's revenues in 2026? - MSN
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price Is Right But Growth Is Lacking After Shares Rocket 34% - 富途牛牛
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug - Investing.com Nigeria
Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Update & High Conviction Buy Zone Alerts - ulpravda.ru
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug By Investing.com - Investing.com South Africa
MarketsMedicine Hat News - FinancialContent
Can Mirum Pharmaceuticals Inc. (08D) stock test all time highsTrade Performance Summary & Weekly Hot Stock Watchlists - ulpravda.ru
Is Mirum Pharmaceuticals Inc. (08D) stock undervalued after correctionJuly 2025 Institutional & Risk Managed Investment Entry Signals - Улправда
Will Mirum Pharmaceuticals Inc. stock benefit from infrastructure spendingWeekly Stock Report & Risk Controlled Daily Plans - Улправда
Mirum Pharmaceuticals Inc (MIRM) 財務データ
収益
当期純利益
現金流量
EPS
3.31%
2.06%
大文字化:
|
ボリューム (24 時間):